Across TCGA pan-cancer cohorts, SLC35E2B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SLC35E2B data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher SLC35E2B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SLC35E2B expression acts as an unfavorable survival marker, although some lineages such as OV and UCEC show a favorable association.

OV, UCEC, and LUAD are the cancer types where SLC35E2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	1.000	0.593	.044	4	view →
UCEC	OS	Median	All	1.000	0.860	.037	4	view →
LUAD	DFS	Median	III,IV	0.256	0.892	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SLC35E2B tumor-vs-normal RNA expression · all SLC35E2B data types